{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T17:22:04Z","timestamp":1787419324943,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100022238","name":"Laboratoire d'Excellence DEVweCAN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020549","name":"Centre L\u00e9on B\u00e9rard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020147","name":"European Network for Rare Adult Solid Cancers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116930","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:44:04Z","timestamp":1783529044000},"page":"116930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort"],"prefix":"10.1016","volume":"245","author":[{"given":"Clio","family":"Coste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Brahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Tirode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Karanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gualter","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Sunyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Combemale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amini-Adle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116930_bib1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41388-022-02290-1","article-title":"Malignant peripheral nerve sheath tumor: models, biology, and translation","volume":"41","author":"Somatilaka","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2026.116930_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant Peripheral Nerve Sheath Tumors","volume":"19","author":"Farid","year":"2014","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejca.2026.116930_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/neuonc\/nos287","article-title":"Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1","volume":"15","author":"Kolberg","year":"2013","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib4","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"961-970","key":"10.1016\/j.ejca.2026.116930_bib5","article-title":"Radiation-Induced Malignant Peripheral Nerve Sheath Tumors: A Systematic Review","volume":"105","author":"Yamanaka","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ejca.2026.116930_bib6","first-page":"65","article-title":"Salvage rates and prognostic factors after relapse in children and adolescents with malignant peripheral nerve sheath tumors","author":"Bergamaschi","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2026.116930_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1\u2014a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2026.116930_bib8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2026.116930_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.24755","article-title":"Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign","volume":"116","author":"Benz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116930_bib10","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1200\/JCO.19.00114","article-title":"Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1","volume":"37","author":"Bhatia","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib11","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ijc.33201","article-title":"Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors","volume":"148","author":"Nishida","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116930_bib13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-24-2807","article-title":"Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models","volume":"31","author":"Ortega-Bertran","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116930_bib14","first-page":"OF1","article-title":"SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST","author":"Kim","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116930_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-026-01303-6","article-title":"Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial","author":"Sveen","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib16","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1038\/s41467-023-38432-6","article-title":"Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities","volume":"14","author":"Suppiah","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116930_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104829","article-title":"Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets","volume":"97","author":"H\u00f8land","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2026.116930_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/gcc.23026","article-title":"Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis","volume":"61","author":"Macagno","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2026.116930_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.2174","article-title":"Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity","volume":"16","author":"Chibon","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116930_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.ejca.2026.116930_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12957-023-03296-z","article-title":"Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis","volume":"22","author":"Lim","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70263","article-title":"Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study","volume":"132","author":"Aubrey","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116930_bib23","doi-asserted-by":"crossref","DOI":"10.1227\/neu.0000000000003981","article-title":"Clinical Outcomes Following Surgical Resection for Patients With Malignant Peripheral Nerve Sheath Tumors","author":"Alfonzo Horowitz","year":"2026","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2026.116930_bib24","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/annonc\/mdr610","article-title":"Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions","volume":"23","author":"Ray-Coquard","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/PAS.0000000000000655","article-title":"Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database","volume":"40","author":"Le Guellec","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2026.116930_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/neuonc\/noae235","article-title":"Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1","volume":"27","author":"Lucas","year":"2025","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138386","article-title":"Diagnostic Accuracy of PET\/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients","volume":"10","author":"Brahmi","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2026.116930_bib28","doi-asserted-by":"crossref","first-page":"zrae024","DOI":"10.1093\/bjsopen\/zrae024","article-title":"Local recurrence in malignant peripheral nerve sheath tumours: multicentre cohort study","volume":"8","author":"Jansma","year":"2024","journal-title":"BJS Open"},{"key":"10.1016\/j.ejca.2026.116930_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606.","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1634\/theoncologist.2018-0160","article-title":"A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors","volume":"24","author":"D\u2019Adamo","year":"2019","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejca.2026.116930_bib32","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1158\/1078-0432.CCR-24-3610","article-title":"MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116930_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","article-title":"Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA","volume":"13","author":"Cortes-Ciriano","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116930_bib35","doi-asserted-by":"crossref","first-page":"72860","DOI":"10.18632\/oncotarget.12096","article-title":"Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma","volume":"7","author":"Shurell","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116930_bib36","article-title":"Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies","volume":"6","author":"Lopez","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2026.116930_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102891","article-title":"Melanoma-associated antigen A4: A cancer\/testis antigen as a target for adoptive T-cell receptor T-cell therapy","volume":"134","author":"Knafler","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116930_bib38","article-title":"Clinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry","volume":"57","author":"Blay","year":"2025","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.ejca.2026.116930_bib39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/jwh.2023.0019","article-title":"Sex Differences in Soft Tissue Sarcoma: Incidence, Clinicopathological Profile, Survival, and Costs","volume":"32","author":"Buja","year":"2023","journal-title":"J Womens Health"},{"key":"10.1016\/j.ejca.2026.116930_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc.2016.30","article-title":"Sexual dimorphism in cancer","volume":"16","author":"Clocchiatti","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116930_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.annonc.2024.01.001","article-title":"Improved nationwide survival of sarcoma patients with a network of reference centers","volume":"35","author":"Blay","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116930_bib42","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/annonc\/mdz124","article-title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","volume":"30","author":"Blay","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:22:07Z","timestamp":1787415727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S0959804926007112"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116930","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116930"}}